Board of Directors
Acting in the interest of shareholders by setting high standards for employees, directors and management of the Company’s business
Sacha Loiseau, Ph.D
Founder, Chairman of the Board and CEO
SACHA FOUNDED MAUNA KEA TECHNOLOGIES IN 2000
Sacha is the co-inventor of the probe-based Confocal Laser Endomicroscopy technology and conducted the development of the Cellvizio product line, raising over €120m with private and public investors, including €56.5m through an IPO in July 2011 on the NYSE Euronext Paris stock exchange. In 2013, Sacha was named co-lead of France’s Re-industrialization Plan for Medical Devices by the French President and then a member of the Committee for the Future of Medicine. Sacha has served as a mentor of the Polytechnique-Stanford Ignite Program for young MedTech entrepreneurs for several years. Sacha was instrumental in the foundation of the association Medtech in France, of which he is Vice-President.
Sacha started his career at the National Center for Space Studies (CNES) in Toulouse and at the Paris Observatory, then joined NASA’s Jet Propulsion Laboratory (JPL) in Pasadena, California, as a research scientist. Sacha is a graduate of Ecole Polytechnique and holds a Ph.D. in Astrophysics and Optical Instrumentation from University Paris-Diderot. He is the author of multiple scientific papers and holds 7 international patents and was the 2018 recipient of the Marius Lavet Prize.
Christopher D. McFadden, CFA
Member of the Board
Chair of the compensation and nomination committee
MANAGING DIRECTOR AT APOLLO GLOBAL MANAGEMENT
Molly O’Neill
Member of the Board
EXPERIENCED GLOBAL HEALTHCARE GROWTH AND STRATEGY EXECUTIVE
Molly O’Neill brings over 30 years of experience developing growth strategies to increase market share and revenue of P/E backed, public company, academic, and not-for-profit health care organizations. She is a recognized leader at some of the world’s most prestigious healthcare delivery systems with ground- breaking product development achievements in medical education, medical devices and digital health.
Currently, Ms. O’Neill serves as the Chief Strategic Partnerships Officer for Aegis Ventures, a next-generation venture studio that partners with leading health systems, entrepreneurs and industry leaders to originate, launch, and scale transformative companies. She has led strategy and business development as a Vice Chancellor of Duke Medicine, Executive Director of Specialty Care for Mass General Brigham and provided national growth leadership at Tenet Healthcare, Ascension Health Care Network and Inova Health System.
Claire Biot
Member of the Board
Claire Biot is Vice President, Life Sciences Industry, Dassault Systèmes, where she is responsible for long-term growth strategy in Life Sciences and Healthcare, as well as go-to-market strategy with the existing portfolio of solutions.
Prior to joining Dassault Systèmes, she was Managing Director of Health Products and Technologies Central Agency, a subsidiary of Greater Paris University Hospitals (AP-HP). Previously, she was Head of Division, Health Products Pricing and Reimbursement at the French Ministry of Health.
In addition to engineering degrees from France’s Ecole Polytechnique and the Corps des mines program, Claire Biot earned a Master of Science degree in life sciences from Cold Spring Harbor Laboratory, NY, USA, and a PhD in immunology from the Institut Pasteur.
Jacquelien ten Dam
Member of the Board
Chair of the Audit Committee
Jacquelien ten Dam is Chief Financial Officer at Mimetas where she is responsible for the Corporate Development and Finance activities.
Mimetas uses it proprietary organ-on-a-chip platform to unravel disease biology to find novel therapies. Prior to joining Mimetas she worked at Picnic, one of the most disruptive start-ups in the Netherlands, playing a key role in accelerating the company’s B2B business. She led the team that provides big data consultancy and ecommerce advice to FMCG companies such as PepsiCo, Unilever and AB InBev.
Jacquelien started her career at Kempen Co, a European investment bank where she advised in numerous international capital market transactions including IPOs, secondary fundraisings and MA transactions for companies such as Galapagos, ALK and QIAGEN. Jacquelien holds an MSc. degree from Leiden University in Biomedical Sciences. She has lived and worked in the US (UCLA), India (Dr. Reddy’s Laboratories) and the Netherlands.
News
YOU MIGHT ALSO LIKE TO READ
Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex
Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update
Mauna Kea Technologies Announces its 2025 Financial Calendar
Find out more by downloading the
Cellvizio Brochure